Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Preclinical | CH | 22 May 2023 |